Elin Rosendahl - Vicore Pharma VP Devel

All Insiders . Sweden . 
Stock . Vicore Pharma Holding . Stakeholders . Insider . Elin Rosendahl
VICO Stock  SEK 7.86  0.21  2.75%   

Insider

Elin Rosendahl is VP Devel of Vicore Pharma Holding
Phone46 3 17 88 05 60
Webhttps://www.vicorepharma.com

Vicore Pharma Management Efficiency

The company has return on total asset (ROA) of (0.4902) % which means that it has lost $0.4902 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.9886) %, meaning that it generated substantial loss on money invested by shareholders. Vicore Pharma's management efficiency ratios could be used to measure how well Vicore Pharma manages its routine affairs as well as how well it operates its assets and liabilities.
Vicore Pharma Holding has accumulated 320 K in total debt. Vicore Pharma Holding has a current ratio of 19.43, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Vicore Pharma until it has trouble settling it off, either with new capital or with free cash flow. So, Vicore Pharma's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Vicore Pharma Holding sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Vicore to invest in growth at high rates of return. When we think about Vicore Pharma's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Carina AkerstromSvenska Handelsbanken AB
61
Patrick JamnikEpisurf Medical AB
40
Mattias ForsbergSvenska Handelsbanken AB
51
Paul EchtMedia and Games
N/A
Alexander ErnrydFractal Gaming Group
38
Yonnie BergqvistSvenska Handelsbanken AB
62
Lars hrnNexam Chemical Holding
52
Katarina FlodstrmEpisurf Medical AB
48
Magnus EricsonSvenska Handelsbanken AB
55
Christer SvanbergNexam Chemical Holding
N/A
Ionut CiobotaruMedia and Games
37
Lucas PeterssonNexam Chemical Holding
31
Carl CederschioldSvenska Handelsbanken AB
50
Thomas JacobsenMedia and Games
N/A
Jonas HolstFractal Gaming Group
39
Soren BarzMedia and Games
N/A
Pr OxelheimMTI Investment SE
N/A
Beata LihammarEpisurf Medical AB
N/A
Sameer SondhiMedia and Games
48
Lina BrattstromSaveLend Group AB
N/A
Jonas AhlbergSaveLend Group AB
57
Vicore Pharma Holding AB , through its subsidiaries, operates as a biotech company. Vicore Pharma Holding AB was founded in 2000 and is based in Mlndal, Sweden. Vicore Pharma is traded on Stockholm Stock Exchange in Sweden. Vicore Pharma Holding (VICO) is traded on Stockholm Exchange in Sweden and employs 23 people.

Management Performance

Return On Equity-0.99
Return On Asset-0.49

Vicore Pharma Holding Leadership Team

Elected by the shareholders, the Vicore Pharma's board of directors comprises two types of representatives: Vicore Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vicore. The board's role is to monitor Vicore Pharma's management team and ensure that shareholders' interests are well served. Vicore Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vicore Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
Kicki Johansson, Chief Officer
Johan Raud, Chief Officer
Elin Rosendahl, VP Devel
Nina Carlen, Chief Officer
Asa Magnusson, Chief Officer
Rohit Batta, Chief Officer
Hans Jeppsson, Chief Officer
CarlJohan MD, Chief Officer
Jessica Shull, Head Therapeutics
Johanna Grans, Head Devel

Vicore Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vicore Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.99
Return On Asset-0.49
Current Valuation1.22 B
Shares Outstanding81.85 M
Shares Owned By Insiders16.14 %
Shares Owned By Institutions51.89 %
Price To Earning163.82 X
Price To Book8.67 X
EBITDA(293.13 M)
Net Income(296.48 M)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Vicore Stock Analysis

When running Vicore Pharma's price analysis, check to measure Vicore Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vicore Pharma is operating at the current time. Most of Vicore Pharma's value examination focuses on studying past and present price action to predict the probability of Vicore Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vicore Pharma's price. Additionally, you may evaluate how the addition of Vicore Pharma to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY